Association of cyclin D and estrogen receptor α36 with hepatocellular adenomas of female mice under chronic endoplasmic reticulum stress

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 3, 2013, Pages 576-583

  Lau, Mo Yin ^a   Han, Hui ^a   Hu, Jay ^a   Ji, Cheng ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Abnormal function of cyclin D; Hepatocellular tumorigenesis; High fat diet (HFD); Metabolic stress; Sex hormone receptor variants; Unfolded protein response (UPR)

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ALPHA; BETA CATENIN; CYCLIN D; CYCLIN E; CYCLIN G; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; ESTROGEN RECEPTOR BETA; GLYCOGEN SYNTHASE KINASE 3BETA; GLYPICAN 3; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FEMALE; HEPATOCELLULAR ADENOMA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIVER ADENOMA; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 84874396130     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12084     Document Type: Article

References (42)

1. Ozcan L, Tabas I. Role of endoplasmic reticulum stress in metabolic disease and other disorders. Annu. Rev. Med. 2012; 63: 317-328.
2. Wang G, Yang ZQ, Zhang K. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am. J. Transl. Res. 2010; 2: 65-674.
3. Wu X, Sun L, Zha W, Studer E, Gurley E, Zhou H. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2010; 138: 197-209.
4. Ji C. Dissection of endoplasmic reticulum stress signaling in alcoholic and non-alcoholic liver injury. J. Gastroenterol. Hepatol. 2008; 23 (Suppl. 1): S16-24.
5. Ji C. Mechanisms of alcohol-induced endoplasmic reticulum stress and organ injuries. Biochem. Res. Int. 2012; 216450: 1-12.
6. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 2006; 6: 45-54.
7. Kammoun HL, Chabanon H, Hainault I etal. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Invest. 2009; 119: 1201-1215.
8. Ji C, Kaplowitz N, Lau MY, Kao E, Petrovic LM, Lee AS. Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice. Hepatology 2011; 54: 229-239.
9. Kao E, Shinohara M, Feng M, Lau MY, Ji C. Human immunodeficiency virus protease inhibitors modulate Ca(2+) homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes. Hepatology 2012; 56: 594-604.
10. Ji C, Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 2003; 124: 1488-1499.
11. Fauci AS, Braunwald E, Kasper DL etal. Harrison's Principles of Internal Medicine, 17th edn. New York: McGraw-Hill Medical, 2008; Chapter 92 (benign liver tumors).
12. Bioulac-Sage P, Taouji S, Possenti L, Balabaud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int. 2012; 32: 1217-1221.
13. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin. Liver Dis. 2011; 31: 173-187.
14. Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics 2011; 31: 1529-1543.
15. Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J. Gastroenterol. Hepatol. 2011; 26: 28-35.
16. Capurro M, Wanless IR, Sherman M etal. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.
17. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Focal nodular hyperplasia, hepatocellular adenomas: past, present, future. Gastroenterol. Clin. Biol. 2010; 34: 355-358.
18. Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin. Liver Dis. 2011; 31: 91-103.
19. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N. Engl. J. Med. 1976; 294: 470-472.
20. Guichard C, Amaddeo G, Imbeaud S etal. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012; 44: 694-698.
21. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 2012; 142: 219-232.
22. Brewer JW, Hendershot LM, Sherr CJ, Diehl JA. Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 8505-8510.
23. Brewer JW, Diehl JA. PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 12625-12630.
24. Hamanaka RB, Bennett BS, Cullinan SB, Diehl JA. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol. Biol. Cell 2005; 16: 5493-5501.
25. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 2009;220: 292-296.
26. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011; 11: 558-572.
27. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145: 5439-5447.
28. Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 1998; 58: 2876-2880.
29. Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR, Sloane JP. Immunodetectablecyclin D(1) is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br. J. Cancer 2001; 84: 1064-1069.
30. Ledda-Columbano GM, Pibiri M, Concas D, Cossu C, Tripodi M, Columbano A. Loss of cyclin D1 does not inhibit the proliferative response of mouse liver to mitogenic stimuli. Hepatology 2002; 36: 1098-1105.
31. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88: 405-415.
32. Vranic S, Gatalica Z, Deng H etal. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J. Clin. Pathol. 2011; 64: 54-57.
33. Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36). J. Biol. Chem. 2012; 287: 7169-7181.
34. Wang J, Li J, Fang R, Xie S, Wang L, Xu C. Expression of ERα36 in gastric cancer samples and their matched normal tissues. Oncol. Lett. 2012; 3: 172-175.
35. Zhang XT, Ding L, Kang LG, Wang ZY. Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells. Oncol. Rep. 2012; 27: 2057-2065.
36. Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36). J. Biol. Chem. 2012; 287: 7169-7181.
37. Miceli V, Cocciadiferro L, Fregapane M etal. Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. OMICS 2011; 15: 313-317.
38. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal. 2008; 20: 581-589.
39. Lin SL, Yan LY, Zhang XT etal. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS ONE 2010; 5: e9013.
40. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2012; 32: 1-13.
41. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem. Sci. 2008; 33: 122-131.
42. He G, Karin M. NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res. 2011; 21: 159-168.